ethyl 4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylate | 741287-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylate
• 英文别名: 4-Methyl-1,5-diphenyl-1H-pyrazole-3-carboxylic acid ethyl ester；ethyl 4-methyl-1,5-diphenylpyrazole-3-carboxylate
• CAS: 741287-00-3
• 化学式: C₁₉H₁₈N₂O₂
• 分子量: 306.364
• InChiKey: FAQVLYUQRDUSOQ-UHFFFAOYSA-N

物化性质

• 沸点：
  455.3±33.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 以1.01 g的产率得到4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  “One-Pot” Synthesis of 4-Substituted 1,5-Diaryl-1H-pyrazole-3-carboxylic Acids via a MeONa/LiCl-Mediated Sterically Hindered Claisen Condensation–Knorr Reaction–Hydrolysis Sequence

  摘要：

  A "one-pot" synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylic acids was first reported in moderate to good yields. This concise procedure, featuring efficiency and green chemistry, was composed of MeONa/LiCl-mediated sterically hindered Claisen condensation, Knorr reaction and hydrolysis.

  DOI：

  10.1055/s-0032-1317668
• 作为产物：
  描述：

  苯丙酮 在 硫酸 、 lithium hexamethyldisilazane 作用下， 以 乙醇 、 正己烷 、 环己烷 、 水 为溶剂， 反应 32.25h， 生成 ethyl 4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  新型抗肥胖药：利莫那班和LH21类似物的合成和药理评价

  摘要：

  为了寻找新型的抗肥胖药，已经制备了一系列大麻素LH21和利莫那班-脂肪酸酰胺类似物。吡唑2a – 2c的合成是通过两步简单的方法，通过α，β-不饱和酮实现的。通过在温和条件下进行的一锅法操作，从酯7a - 7c中以高收率获得了羧酰胺8a - 8h。已经在体内评估了新化合物作为厌食药的作用。他们中的一些人表现出令人感兴趣的特性，其通过不涉及内源性大麻素系统的机制减少了大鼠的食物摄入。

  DOI：

  10.1016/j.bmc.2013.01.055
• 作为试剂：
  描述：

  苯甲醛 、 2,2,6,6-tetramethyl-piperidine-N-oxyl 在 叔丁基过氧化氢 、 ethyl 4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylate 、 palladium(II) trifluoroacetate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 12.0h， 以63%的产率得到(2,2,6,6-四甲基哌啶-1-基)苯甲酸酯
  参考文献：
  名称：

  通过芳族CH键的活化，钯催化的全取代吡唑的后期单芳基化

  摘要：

  摘要通过直接和排他的单-Csp2 H键活化，具有宽的底物范围和良好的官能团耐受性，开发了钯催化的4-甲基-1,5-二芳基-1H-吡唑-3-羧酸酯的后期芳基化反应。X射线单晶晶体学证实了双核二聚体帕拉达环，并且可能在催化循环中用作活性物质。

  DOI：

  10.1016/j.cclet.2018.09.022

文献信息

• ‘One-pot’ synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates via lithium tert-butoxide-mediated sterically hindered Claisen condensation and Knorr reaction
  作者：Jian-An Jiang、Wei-Bin Huang、Jiao-Jiao Zhai、Hong-Wei Liu、Qi Cai、Liu-Xin Xu、Wei Wang、Ya-Fei Ji

  DOI：10.1016/j.tet.2012.11.012

  日期：2013.1

  A concise ‘one-pot’ synthesis of a variety of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates has been developed in moderate to good yields with excellent regioselectivity. Less cost lithium tert-butoxide has been identified as a base for sterically hindered Claisen condensation to efficiently generate the labile 3-substituted 4-aryl-2,4-diketoesters. Furthermore, extensive studies lead to a ‘one-pot’

  已经开发了一种简单的“一锅法”合成的各种4-取代的1,5-二芳基-1 H-吡唑-3-羧酸酯，具有中等到良好的产率，具有出色的区域选择性。成本较低的叔丁醇锂已被确定为空间受阻克莱森（Claisen）缩合反应的碱，可有效生成不稳定的3-取代的4-芳基-2,4-二酮酸酯。此外，广泛的研究通过克莱森缩合反应和克诺尔反应相结合而合成“有价值的4-取代的1,5-二芳基-1 H-吡唑-3-羧酸酯”的“一锅法”工艺。
• Pyrazole derivative
  申请人：Kanaya Naoaki

  公开号：US20060128685A1

  公开（公告）日：2006-06-15

  The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.

  本发明旨在提供一种强的血小板聚集抑制剂，其不抑制COX-1或COX-2。本发明提供了由式（I）或式（II）表示的化合物，化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂，其中包含任何一种化合物、盐或溶剂。
• Cannabinoid Receptor Modulators
  申请人：Receveur Jean Marie

  公开号：US20100292273A1

  公开（公告）日：2010-11-18

  Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein: X is a bond, or a divalent radical selected from —C(R 10 )(R 11 )—*, —C(R 10 )(R 11 )—O—*, —C(R 10 )(R 11 )CH 2 —*, —C(R 10 )(R 11 )CH 2 —O—*, —CH 2 C(R 10 )(R 11 )—*, —CH 2 C(R 10 )(R 11 )—O—*. and —CH 2 —O—C(R 10 )(R 11 )—*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is a carboxyl isostere radical selected from the group specified; R 3 is hydrogen, (C 1 -C)alkyl or (C 1 C 3 )fluoroalkyl; R 4 is a radical of formula -(Alk 1 ) p -(Q 1 ) r (L) s -Q 2 wherein p, r, s, Alk 1 , L, Q 1 and Q 2 are as specified; or R 3 and R 4 taken together with the nitrogen to which they are attached form a cyclic amino ring of 4 to 7 ring atoms which is optionally substituted by a radical of formula -(L) s -Q 2 wherein s, L and Q 2 are as defined above, or by an optional substituent selected from hydroxy, methoxy, —NH 2 —, or mono- or di-(C 1 C 3 )alkylamino; R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen —F, —Cl, —Br, —CN, (C 1 -C 3 )alkyl, (C 1 C 3 )fluoroalkyl, cyclopropyl, and —OR 9 ; R 10 is hydrogen, (C 1 C 3 )alkyl, hydroxyl or NH 2 , and R 11 is hydrogen or (C 1 -C 3 )alkyl; or R 10 and R 11 taken together with the carbon atom to which they are attached form a (C 3 -C 5 )cycloalkyl ring.

  式(I)的化合物是大麻素受体CB1的调节剂，可用于肥胖症的治疗：式(I)。其中：X是键或二价基团，选择自-C(R10)(R11)-*，-C(R10)(R11)-O- *，-C(R10)(R11)CH2- *，-C(R10)(R11) -O- *，- C(R10)(R11)-*，- C(R10)(R11)-O- *和- -O-C(R10)(R11)-*，其中由星号表示的键连接到吡唑环；Z是羧基异构基团，选择自指定的群组；R3是氢，(C1-C)烷基或(C1C3)氟烷基；R4是式-(Alk1)p-(Q1)r(L)s-Q2的基团，其中p，r，s，Alk1，L，Q1和Q2如所述；或R3和R4与它们所连接的氮一起形成4到7个环原子的环状氨基环，可选地被式-(L)s-Q2的基团或由上述定义的氢氧化物，甲氧基，-NH2-或单或双-(C1C3)烷基氨基取代；R5、R6、R7和R8各自独立地选择自氢，-F，-Cl，-Br，-CN，(C1-C3)烷基，(C1C3)氟烷基，环丙基和-OR9；R10是氢，(C1C3)烷基，羟基或NH2，R11是氢或(C1-C3)烷基；或R10和R11与它们所连接的碳原子一起形成(C3-C5)环烷基环。
• PYRAZOLE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1591443B1

  公开（公告）日：2010-08-25
• 1,5-Diarylpyrazole and vanillin hybrids: Synthesis, biological activity and DFT studies
  作者：Eduardo Hernández-Vázquez、Romina Castañeda-Arriaga、Juan José Ramírez-Espinosa、Omar Noel Medina-Campos、Francisco Hernández-Luis、José Pedraza Chaverri、Samuel Estrada-Soto

  DOI：10.1016/j.ejmech.2015.06.010

  日期：2015.7

  Herein, we report the design and synthesis of 13 diarylpyrazole hybrids with vanillin constructed as dual compounds against oxidative stress and diabetes. Compounds were tested in two different antioxidant assays. It was found that all compounds showed an important antioxidant activity in both DPPH and ORAC models and the activity was even more remarkable than vanillin. In addition, the hypoglycemic effect of compounds 1, 2, 4 and 12 was evaluated. Interestingly, compound 1 had the most potent hypoglycemic effect with a glycemia reduction of 71%, which was higher than rimonabant. Finally, a DFT study to propose a reasonable antioxidant mechanism is detailed. Both thermodynamic and kinetic studies indicated that the most feasible mechanism consists in the HAT abstraction of the phenolic hydrogen due to the formation of an stable transition state through the most rapid and exergonic path, while the SPLET mechanism is the most significant at higher pH values. (C) 2015 Elsevier Masson SAS. All rights reserved.